In modern cardiovascular and surgical healthcare, Enoxaparin Sodium remains the gold-standard low molecular weight heparin (LMWH), delivering predictable, safe anticoagulation for millions worldwide. As the global market surges—projected to reach USD 4.31 billion by 2026 with a 6.7% CAGR—pharmaceutical partners demand a reliable source of high-purity Enoxaparin Sodium that meets strict international standards. Jiulong stands as a premier supplier, combining decades of heparin expertise, GMP-compliant manufacturing, and rigorous quality control to provide Enoxaparin Sodium that empowers life-saving treatments across North America, Europe, Asia-Pacific, and beyond.
Enoxaparin Sodium is integral to preventing deep vein thrombosis (DVT), pulmonary embolism (PE), and managing acute coronary syndromes (ACS), with broad applications in orthopedic, abdominal, and cardiac surgery, as well as long-term medical care. Jiulong’s Enoxaparin Sodium is derived from premium porcine intestinal mucosa heparin, processed via controlled benzyl esterification and alkaline depolymerization to ensure precise molecular weight distribution (average 4500 Da) and optimal anti-Xa/anti-IIa activity ratios. Our advanced production lines employ automated chromatography, ultrafiltration, and fractional alcohol precipitation technologies, achieving purity levels exceeding 99%—far exceeding EP, USP, and ChP pharmacopeial requirements.
What distinguishes Jiulong’s Enoxaparin Sodium is our unwavering commitment to quality assurance and supply stability. Every batch undergoes comprehensive testing: potency validation (anti-Xa ≥ 100 IU/mg), residual solvent analysis, viral inactivation verification, and impurity profiling. Our quality team adheres to ICH Q7 and EU GMP guidelines, with full process validation and traceability from raw material to finished API. We maintain a robust, vertically integrated supply chain, ensuring consistent availability even during market fluctuations. Flexible manufacturing capacities accommodate small-batch R&D orders and large-scale commercial production, supporting partners from clinical trials to global distribution.
Global healthcare systems increasingly prioritize cost-effective, high-quality generics, and Jiulong’s Enoxaparin Sodium answers this need without compromising safety or efficacy. In Europe, our product complies with EMA biosimilar standards, facilitating seamless market access for finished dosage manufacturers. In North America, we meet FDA requirements, supporting approved indications for DVT prophylaxis, PE treatment, and ACS management. Across Asia-Pacific, we offer competitive pricing and responsive service, aligning with the region’s growing demand for reliable anticoagulant APIs.
Beyond product excellence, Jiulong provides end-to-end partnership support: custom formulation guidance, regulatory dossier preparation (DMF, CEP), and stability testing to accelerate client product launches. Our technical experts collaborate closely with partners to optimize production workflows, ensuring Enoxaparin Sodium integrates seamlessly into finished injectables, pre-filled syringes, and autoinjectors. This holistic approach has made Jiulong a trusted name for pharmaceutical companies, hospitals, and distributors seeking a dependable Enoxaparin Sodium supplier.
As the global burden of thrombotic disorders rises with aging populations and increased surgical volumes, Enoxaparin Sodium will remain indispensable. Jiulong continues to innovate, refining manufacturing processes to enhance sustainability and reduce environmental impact while upholding the highest quality benchmarks. Our dedication to ethical sourcing, regulatory compliance, and customer success positions us as a leader in the global LMWH market.
For businesses seeking premium Enoxaparin Sodium to elevate their anticoagulant portfolios, Jiulong offers unmatched quality, reliability, and service. Contact us today to request product samples, discuss custom specifications, or explore how our industry-leading API can support your global healthcare initiatives and drive mutual success.